BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

The European Commission has approved Bristol Myers Squibb's subcutaneous formulation of Opdivo (nivolumab) for multiple solid tumor indications, making it the first and only PD-1 inhibitor approved for subcutaneous use in the EU; this approval, which covers all 27 EU member states plus Iceland, Norway, and Liechtenstein, was supported by data from the CheckMate -67T study, showing comparable pharmacokinetics and safety profile to the intravenous version. While Opdivo SC is already approved in the US under the name Opdivo Qvantig, Bristol Myers Squibb shares have declined 17% year-to-date, lagging the industry's 5.4% decline.

Analysis

Bristol Myers Squibb (BMY) has secured European Commission approval for its subcutaneous (SC) formulation of Opdivo (nivolumab) across multiple solid tumor indications, a significant development making it the first and only PD-1 inhibitor available for SC administration in the European Union, Iceland, Norway, and Liechtenstein. This approval, supported by the CheckMate -67T study in adults with advanced or metastatic clear cell renal cell carcinoma, demonstrated comparable pharmacokinetics (Cavgd28 geometric mean ratio 2.10, Cminss geometric mean ratio 1.77 versus IV) and safety to the intravenous (IV) version, with an objective response rate of 24% in the SC group versus 18% in the IV group. This follows the SC formulation's prior approval in the United States as Opdivo Qvantig. Despite this positive regulatory news and Opdivo's established role, BMY's shares have declined 17% year-to-date, significantly underperforming the industry’s 5.4% decline; BMY currently carries a Zacks Rank #3 (Hold). In contrast, the article presents Bayer (BAYRY), Lexicon Pharmaceuticals (LXRX), and Amarin (AMRN) as Zacks Rank #2 (Buy) rated biotech stocks. Bayer has seen 2025 EPS estimates increase from $1.19 to $1.25 and its shares gain 43.2% YTD, though it had an average negative earnings surprise of 13.91% in the trailing four quarters. Lexicon's 2025 loss per share estimates narrowed from 37 to 32 cents, but its shares fell 5.3% YTD, despite an average positive earnings surprise of 11.97%. Amarin's 2025 loss per share estimates also narrowed significantly from $5.33 to $3.48, its shares gained 16.4% YTD, and it posted an average positive earnings surprise of 29.11%.

Key Decisions for Investors

• Investors in Bristol Myers (BMY) should view the EU approval of subcutaneous Opdivo as a positive long-term catalyst for the franchise, potentially improving patient convenience and adherence, though the current share price underperformance of 17% year-to-date warrants scrutiny of broader company or market factors.
• It is advisable to monitor the commercial uptake of Opdivo SC in the EU and its impact on BMY's revenue growth in upcoming quarters, alongside any management commentary on addressing the stock's significant YTD decline relative to the industry.
• Consider evaluating the mentioned alternative biotech investments like Bayer (BAYRY), Lexicon (LXRX), and Amarin (AMRN), which currently have a 'Buy' rating from Zacks and positive earnings estimate trends, while conducting thorough due diligence on their respective risk profiles, stock performance, and historical earnings consistency as highlighted.